TB-500
$Product-identity problem; Preclinical wound-healing rationale
TB-500 is commonly marketed as a tissue-repair peptide related to thymosin beta-4, but the name is not precise. In FDA compounding safety-risk language, TB-500 refers to the thymosin beta-4 fragment LKKTETQ. Full-length thymosin beta-4/Tβ4 is a different 43-amino-acid peptide.
Full-length Tβ4 has broader wound, corneal, inflammatory, and cardiac research context. That evidence should not be automatically transferred to TB-500/LKKTETQ or to vendor-labeled TB-500 vials. Verify sequence identity first.
Pharmacokinetics, oxidation assumptions, safety, and evidence grade depend on whether the product is LKKTETQ fragment, full-length Tβ4, N-acetylated fragment, salt form, blend, or mislabeled compound.
The first classification step is identity control. TB-500 and full-length thymosin beta-4/Tβ4 should not be used as interchangeable names unless the product documentation proves it.
Classification details
- FDA-described TB-500 is thymosin beta-4 fragment LKKTETQ, a heptapeptide fragment.
- Full-length thymosin beta-4/Tβ4/timbetasin is a naturally occurring 43-amino-acid actin-sequestering peptide found in many tissues and wound contexts.
- Vendor-labeled TB-500 may refer to LKKTETQ fragment, N-acetylated fragment, full-length Tβ4, salt forms, a blend component, or inaccurately labeled material.
- The key identity issue is sequence: LKKTETQ and full-length Tβ4 have different residue profiles, likely different PK, and different evidence boundaries.
- COA review to distinguish exact makeup should include full HPLC/UPLC purity, high-resolution mass-spec identity, expected molecular mass, sequence confirmation when possible, endotoxin testing, sterility testing, and blend-specific content where applicable.
- FDA-described TB-500/LKKTETQ fragment, full-length thymosin beta-4, and unresolved vendor-labeled TB-500 are three different things. These are not interchangeable for sequence, mechanism, route evidence, or oxidation assumptions.
The repair rationale for thymosin beta-4-family products centers on actin/cell-migration biology, but the strength and meaning of that claim depends on the exact identity.
- Full-length Tβ4: sequesters G-actin and helps regulate cytoskeletal organization. This is central to cell movement and repair-cell migration.
- TB-500/LKKTETQ: an active-region fragment associated with the actin-binding region. Do not assume it reproduces full-length Tβ4 distribution, half-life, or all biological functions.
- Cell migration: epithelial cells, endothelial cells, keratinocytes, and other repair cells must migrate across damaged tissue. Tβ4-family biology is repeatedly linked to this process.
- Angiogenesis: repair requires blood-vessel support. This may help explain wound-healing signals but also raises cancer and abnormal-angiogenesis caution.
- Anti-inflammatory/anti-fibrotic effects: strongest as full-length Tβ4-family research context, not as proof for every TB-500-labeled product.
- Product-specific uncertainty: fragment, full-length, recombinant, salt, and blend products can differ in receptor/signaling context, immunogenicity, stability, and PK.
- Full-length Tβ4 biology includes actin-binding, cell migration, angiogenesis, and wound-repair signaling. The LKKTETQ fragment may capture only part of this biology, so mechanism claims hold only when they match identity.